Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or
Patents for C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
06/2003
06/25/2003EP1320367A1 Process for the preparation of dinapsoline
06/25/2003EP1320366A1 Substituted piperidines as melanocortin receptor agonists
06/25/2003EP1200442B1 2,3-benzodiazepine derivatives
06/25/2003EP0777703B1 Dicyclic metal complex formazan derivatives, process for producing the same, composition containing the same and dyeing process employing the same
06/25/2003EP0641343B1 4-mercaptoacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
06/25/2003CN1426414A Prodrugs of imidazopyridine derivatives
06/25/2003CN1426405A 新型环状酰胺衍生物 Novel cyclic amide derivative
06/25/2003CN1426398A Condensed heteroaryl derivatives
06/25/2003CN1425666A Method for extracting tetrodotoxin
06/25/2003CN1425665A Process for preparing 2-chlorobenzo imidazole derivative
06/25/2003CN1112365C Piperidine derivatives and preparing method and use
06/24/2003US6583319 Cyclic compounds having a cycloalkylene chain
06/24/2003US6583183 Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
06/24/2003US6583168 Sulfonated diarylrhodamine dyes
06/24/2003US6583166 Fewer side effects than D2 receptor antagonist neuroleptics; cardiovascular, kidney, central nervous system disorders; 3-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl) propyl)-1,3,3a,4,5,9b-hexahydro-2H-benzo(e)indol-2-one
06/24/2003US6583161 Benzenesulfonamides and benzamides as therapeutic agents
06/24/2003US6583154 Compounds and methods which modulate feeding behavior and related diseases
06/19/2003WO2003050122A2 Mitotic kinesin inhibitors
06/19/2003WO2003050099A1 Phenylalkynes
06/19/2003WO2003049741A1 Ureas of 2-aminobenzothiazoles as adenosine modulators
06/19/2003WO2003020252A3 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
06/19/2003US20030114679 Selective hydrogenation of amino-substituted fused bicyclic aromatic ring system, preparation of racemic amino substituted fused bicyclic ring system via nitrosation, enzymatic resolution of racemic mixture to produce (R)- and (S)-forms
06/19/2003US20030114678 Cardioprotective phosphonates and malonates
06/19/2003US20030114677 Cardioprotective phosphonates and malonates
06/19/2003US20030114666 Antibacterial agents
06/19/2003US20030114508 Fused imidazolium derivatives
06/19/2003US20030114485 Killing drug resistant cancer cells; controlling cell differentiation
06/19/2003US20030114458 Antibacterial agents
06/19/2003US20030114454 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
06/19/2003US20030114450 Benzoquinone ansamycins
06/19/2003US20030114437 Protease inhibitors
06/19/2003US20030114432 Antiinflammatory agents; rheumatic diseases; anticancer agents
06/19/2003US20030114424 Treatment of cerebrovascular disease
06/19/2003US20030114420 Anticancer agents, autoimmunine diseases, congestive heart failure, skin disorders, antiinflammatory agents
06/19/2003US20030114365 Neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins; treating neurodegenrative disorders
06/19/2003US20030113665 Optical data medium containing, in the information layer, a dye as a light-absorbing compound
06/19/2003CA2469893A1 Phenylalkynes
06/19/2003CA2469596A1 Ureas of 2-aminobenzothiazoles as adenosine modulators
06/19/2003CA2467726A1 Mitotic kinesin inhibitors
06/18/2003EP1319659A1 Pyridazinones and triazinones and medicinal use thereof
06/18/2003EP1319007A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
06/18/2003EP1318997A1 Pyrazole compounds useful as protein kinase inhibitors
06/18/2003EP1318995A2 Pyridinone and pyridinethione derivatives having hiv inhibiting properties
06/18/2003EP1318980A2 Hydroxamate derivatives useful as deacetylase inhibitors
06/18/2003EP1318978A2 N-acylsulfonamide apoptosis promoters
06/18/2003EP1318837A2 Method of treating estrogen receptor positive carcinoma
06/18/2003EP1318814A2 Triazole compounds useful as protein kinase inhibitors
06/18/2003EP1318811A1 Cyclopentyl modulators of chemokine receptor activity
06/18/2003EP1202627B1 Fungicidal combinations of active substances
06/18/2003CN1425017A Synthetic process for intermediate for ecteinascidin and phthalascidin compounds
06/18/2003CN1425013A Phenyl substituted 4-hydroxy tetrahydropyridone
06/18/2003CN1111535C 42,52,82,8š�-tetrahydro-6H-pyrrolo [3',4':4,5] furo [3,2-b] pyridine-6,8 [7H]-dione derivatives for use in controlling endoparasites and method
06/18/2003CN1111534C Substituted piperidine-epoxide, its preparation and intermediate and use
06/18/2003CN1111527C Sesquilterpenic internal ester compound for antiulcer of alimentary tract
06/17/2003US6579892 Affective disorders; neurotic, stress and somatoform disorders and psychoses, e.g. schizophrenia 3-(3-(6-Methyl-1,2,3,4-tetrahydronaphth-2-ylamino)propylmercap to) -4-methyl-5-phenyl-1,2,4(4H)-triazole
06/17/2003US6579881 Muscle relaxants, antiserotonine agent
06/17/2003US6579879 For therapy of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals
06/17/2003US6579869 Cephalotaxanes: their method of preparation and their use in treatment of cancers, leukemias, parasites, including those resistant to usual chemotherapeutic agents, and as reversal agents
06/12/2003WO2003048122A2 Inhibitors of cytosolic phospholipase a2
06/12/2003WO2003047568A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003WO2003047505A2 Topoisomerase poison agents
06/12/2003WO2002017712A3 Disubstituted benzenes as insecticides
06/12/2003US20030109705 Novel cyanoenamines useful as ligands for modulating gene expression in plants or animals
06/12/2003US20030109700 Antilipemic agents, anticholesterol agents, cardiovascular disorders, antiischemic agents
06/12/2003US20030109567 Antitumor agent which comprises said compound or a physiologically acceptable salt thereof as an active ingredient.
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109528 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
06/12/2003US20030109460 A pharmaceutical preparation which ensures stability and solubility of a hexacyclic camptothecin derivative prepared by adding a ring having a water-soluble group to camptothecin, wherein a pH-adjusting substance and, a sugar or sugar alcohol
06/12/2003US20030106463 Use to provide transparent perylene pigments having excellent application and color properties; mixture with the pigment and rosin
06/12/2003CA2468967A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317451A1 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317445A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1042289A4 Indole]naphthopyrans, preparation, compositions and (co)polymer matrices containing them, synthesis intermediates
06/11/2003EP0892787B1 Novel alpha-hydroxylic acid derivatives, their production and use
06/11/2003CN1111160C Dibenzylisoquinoline alkaloids and medicinal composition and its use
06/10/2003US6576653 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
06/10/2003US6576651 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
06/10/2003US6576644 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
06/10/2003US6576641 For therapy and prophylaxis of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), or a neurodegenerative disease of the eye, including photoreceptor loss in retina
06/10/2003US6576640 Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease
06/10/2003US6576192 Fluoroionophores and their use in optical ion sensors
06/05/2003WO2003045957A1 3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide
06/05/2003WO2003045952A2 Condensed camptothecins as antitumor agents
06/05/2003WO2003045942A2 Chemokine receptor antagonists and methods of use thereof
06/05/2003WO2003045924A1 Substituted aryl 1,4-pyrazine derivatives
06/05/2003WO2003045919A2 Process for the synthesis of amine ethers from secondary amino oxides and uses
06/05/2003WO2003045324A2 14-methyl-epothilones
06/05/2003WO2003045313A2 2-aminoquinoline compounds
06/05/2003US20030105342 Process for stereoselective synthesis of 2-hydroxymethyl chromans
06/05/2003US20030105324 Camptothecin analogs and methods of preparation thereof
06/05/2003US20030105323 Useful as drug for allergic diseases and autoimmune diseases such as systemic lupus erythemathosus; 2-amino-4-(substituted amino)pyrimidine derivatives; suppression of type 2 helper T cell (Th2) immune responses
06/05/2003US20030105102 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity
06/05/2003US20030105100 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
1 ... 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 ... 298